Discovering the molecular mechanisms of cell-to-cell fusion following viral infection

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: 2888968

Grant search

Key facts

  • Disease

    Disease X
  • Start & end year

    2023
    2027
  • Known Financial Commitments (USD)

    $0
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    N/A

  • Research Location

    United Kingdom
  • Lead Research Institution

    UNIVERSITY OF CAMBRIDGE
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Cell-to-cell fusion is a vital biological process occurring naturally across various tissues which is often hijacked by viruses such as influenza, HIV, and SARS-CoV-2 to facilitate their spread within hosts. Despite this, the host cell machinery/mechanisms that modulate cell fusion are not well understood. This project aims to fill this knowledge gap. We will achieve this through the development of a novel high-throughput platform to study cell-to-cell fusion. This platform will permit an unbiased, genome-scale identification of key molecular regulators of cell-to-cell fusion post-viral infection, a venture that will reveal new therapeutic targets to inhibit viral spread. This interdisciplinary project merges expertise from the Nixon-Abell and Knowles labs in molecular biology, CRISPR engineering, microfluidics, and nanofabrication and promises to advance our fundamental understanding of cell fusion and foster the future development of innovative therapeutic strategies. The student will work through cell line establishment, microfluidic platform optimization, and CRISPRi screening, towards validating potential modulators of virally induced cell fusion.